Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIDE-Biliary01: adjuvant rilvegostomig plus chemotherapy after curative-intent resection of biliary tract cancer
CTR20250058Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Jan 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of rilvegostomig in biliary cancer, biliary adenocarcinoma, sponsored by AstraZeneca. Started Jan 2025; status: active.
02
Drugs
rilvegostomig
03
Conditions
biliary cancerbiliary adenocarcinoma
Beyond the preview
Go deeper on CTR20250058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250058.